• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Biomea Fusion Reports Inducement Grant under Nasdaq LR 5635(c)(4)

    GLOBENEWSWIRE

    Biomea Preclinical Data Icovamenib Enhance Effectiveness of GLP-1

    GLOBENEWSWIRE

    Biomea Fusion Reports Q3 2024 Financial Results and Highlights

    GLOBENEWSWIRE

    Biomea Fusion Announces Approval Of “icovamenib” For BMF-219

    GLOBENEWSWIRE

    Biomea Fusion to Host Conference Call and Webcast on Oct 30th

    GLOBENEWSWIRE

    Biomea Fusion To Present At1st ATTD-ASIA 2024 Conference

    GLOBENEWSWIRE

    Biomea Forms Global Scientific Advisory Board for Diabetes

    GLOBENEWSWIRE

    FDA lifts clinical hold on Biomea`s diabetes trials

    REUTERS

    FDA Lifts Clinical Hold On BMF-219 In Diabetes Trials

    GLOBENEWSWIRE

    Biomea Fusion Reports Inducement Grant Under Nasdaq Rule

    GLOBENEWSWIRE

    Biomea Fusion Reports Q2 2024 Financial Results And Highlights

    GLOBENEWSWIRE

    Diabetes biotech stock tanks as FDA imposes full clinical hold

    FIERCE BIOTECH

    U.S. FDA places clinical hold on Biomea`s diabetes trials

    PRESS RELEASE

    Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold

    GLOBENEWSWIRE

    Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule

    GLOBENEWSWIRE

    Biomea Fusion Completes Enrollment 3 Arms BMF-219 Type 2 Diabetes Trial

    GLOBENEWSWIRE

    Biomea Fusion Q1 2024 Results, Highlights

    GLOBENEWSWIRE

    Biomea Fusion: Inducement Grants Under Nasdaq Rule 5635(c)(4)

    GLOBENEWSWIRE

    Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results

    GLOBENEWSWIRE

    Biomea Highlights Initial Data from the Type 1 Diabetes Dosed with BMF-219

    GLOBENEWSWIRE

    Biomea Fusion Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Biomea Fusion Presents Patient Cohorts in COVALENT-111

    GLOBENEWSWIRE

    Biomea Fusion Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Biomea Fusion Highlights Updates and Anticipated 2024 Corporate Milestones

    GLOBENEWSWIRE

    Biomea Announces Dosing of First Type 1 Diabetes Patient in Ph II with BMF-219

    GLOBENEWSWIRE

    Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    Biomea Presents Achievement of MRD-neg in Responder from Phase I of BMF-219

    GLOBENEWSWIRE

    Biomea Announces Doubling Percentage of Patients with Durable HbA1c Reduction

    GLOBENEWSWIRE

    Biomea Presents Data Showing Improved Glycemic Control in PII Study of BMF-219

    GLOBENEWSWIRE

    Biomea Announces Health Canada Clearance of CTA for BMF-219 in Type 1 Diabetes

    GLOBENEWSWIRE

    Biomea Announces Acceptance of Abstracts for Menin Highlighting Glycemic Control

    GLOBENEWSWIRE

    Biomea Fusion Abstract BMF-219: A Novel Therapeutic Agent

    GLOBENEWSWIRE

    Biomea Fusion to Present New Data from Ongoing Phase II of BMF-219

    GLOBENEWSWIRE

    Biomea Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023

    GLOBENEWSWIRE

    Biomea Fusion Reports Third Quarter 2023 Financial Results

    GLOBENEWSWIRE

    Biomea Fusion Announces First Patient Dosed with BMF-500

    GLOBENEWSWIRE

    Biomea Fusion Announces FDA Clearance of IND Application for BMF-219

    GLOBENEWSWIRE

    Biomea Announces FDA and Health Canada Clearance of COVALENT-111 Phase II Study

    GLOBENEWSWIRE

    Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as CMO

    GLOBENEWSWIRE

    Biomea Fusion Reports Second Quarter 2023 Financial Results

    GLOBENEWSWIRE

    BMF-219 Induces Complete Responses in Target AML Patient Population

    GLOBENEWSWIRE

    Biomea Fusion stock soars after release of clinical data on diabetes treatment

    MARKETWATCH

    Biomea Fusion Presents +VE Data from Initial Cohorts of the Ongoing Ph II Study of BMF-219

    GLOBENEWSWIRE

    Biomea Fusion to Present Late Breaking Data Ongoing PhII Trial, COVALENT-111

    FINANCIAL EXPRESS

    Biomea Fusion to Present Late Breaking Data Ongoing PhII Trial, COVALENT-111

    GLOBENEWSWIRE

    Biomea Fusion patents GTPase KRAS inhibitors

    BIOWORLD

    Biomea Fusion Reports First Quarter 2023 FYR and Corporate Highlights

    GLOBENEWSWIRE

    Biomea Fusion Announces FDA Clearance of IND for Covalent FLT3 Inhibitor BMF-500

    GLOBENEWSWIRE

    Biomea Fusion to Present Late Breaking Data Ongoing Ph II Trial, COVALENT-111

    GLOBENEWSWIRE

    Biomea Fusion to Present Data from PII Trial, COVALENT-111, Evaluating BMF-219

    FINANCE YAHOO

    Biomea Fusion Announces Closing of Upsized Public Offering

    GLOBENEWSWIRE

    Biomea Fusion To Present Two Preclinical Posters at 114th AACR Annual Meeting

    GLOBENEWSWIRE

    Biomea Fusion Announces Proposed Public Offering of Common Stock

    GLOBENEWSWIRE

    Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock

    GLOBENEWSWIRE

    Biomea Announces Data from Initial Cohorts of Ongoing PII Study of BMF-219

    GLOBENEWSWIRE

    Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results

    GLOBENEWSWIRE

    Biomea Fusion stock soars on early-stage diabetes data

    ENDPTS

    Biomea Fusion to Host Conference Discuss Initial Ph II Data for BMF-219

    GLOBENEWSWIRE

    Biomea Fusion To Participate In Upcoming Investor Events

    GLOBENEWSWIRE

    Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial of BMF-219

    GLOBENEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.